Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer’s Exubera Cost-Effectiveness Estimates Not Realistic, U.K.’s NICE Says

Executive Summary

Pfizer's cost-effectiveness estimates for Exubera submitted to the U.K.'s National Institute for Health & Clinical Excellence are not in line with clinical realities, a NICE committee said

You may also be interested in...



Pfizer Holding Its Breath On Exubera DTC Advertising To Focus On Education

Pfizer will begin direct-to-consumer advertising for its inhaled insulin therapy Exubera approximately one year after its approval, the company said at a June 10 briefing in Washington, D.C

Pfizer Exubera Post-Market Training Needs Greater Emphasis – Cmte.

Pfizer/Sanofi-Aventis' post-marketing training program for administering the inhaled insulin powder Exubera with a novel mechanical inhaler needs greater focus, FDA's Endocrinologic & Metabolic Drugs Advisory Committee said in a Sept. 8 review

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

UsernamePublicRestriction

Register

MT125529

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel